VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
VINCI SA vs Novartis AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
VINCI SA
DG · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Novartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisComparison highlights
- Moat score gap: Novartis AG leads (65 / 100 vs 57 / 100 for VINCI SA).
- Segment focus: VINCI SA has 7 segments (44.4% in VINCI Construction); Novartis AG has 5 segments (29.3% in Oncology).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Strong.
- Moat breadth: VINCI SA has 7 moat types across 2 domains; Novartis AG has 4 across 3.
Primary market context
VINCI SA
VINCI Construction
Construction and civil engineering contracting (buildings, infrastructure and specialty networks)
Global
Public-sector project owners and private developers/industrial clients
General contractor / civil engineering contractor
44.4%
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Side-by-side metrics
Moat coverage
Shared moat types
VINCI SA strengths
Novartis AG strengths
Segment mix
VINCI SA segments
Full profile >VINCI Autoroutes
Monopoly
VINCI Airports
Oligopoly
Other concessions (incl. VINCI Highways and PPP assets)
Competitive
VINCI Energies
Competitive
Cobra IS
Competitive
VINCI Construction
Competitive
VINCI Immobilier
Competitive
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.